^
    Back
    Association details:
    Biomarker:MYC overexpression
    Cancer:Non Small Cell Lung Cancer
    Drug Class:ROS1 inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    Mol Cancer Res
    Title:

    MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer

    Published date:
    05/04/2022
    Excerpt:
    Using complementary approaches in multiple models, including a MYC-amplified patient-derived cell line and xenograft (LUAD-0006), we established that MYC overexpression induces broad ROS1-TKI resistance….This study functionally characterizes MYC overexpression as a novel form of therapeutic resistance to ROS1 tyrosine kinase inhibitors in non–small cell lung cancer...
    DOI:
    10.1158/1541-7786.MCR-22-0025